These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 32639723)
1. Integrated Approach for Characterizing Bispecific Antibody/Antigens Complexes and Mapping Binding Epitopes with SEC/MALS, Native Mass Spectrometry, and Protein Footprinting. Huang RY; Wang F; Wheeler M; Wang Y; Langish R; Chau B; Dong J; Morishige W; Bezman N; Strop P; Rajpal A; Gudmundsson O; Chen G Anal Chem; 2020 Aug; 92(15):10709-10716. PubMed ID: 32639723 [TBL] [Abstract][Full Text] [Related]
2. Characterization of ELISA Antibody-Antigen Interaction using Footprinting-Mass Spectrometry and Negative Staining Transmission Electron Microscopy. Lin M; Krawitz D; Callahan MD; Deperalta G; Wecksler AT J Am Soc Mass Spectrom; 2018 May; 29(5):961-971. PubMed ID: 29512051 [TBL] [Abstract][Full Text] [Related]
3. Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies. Huang RY; Wang Y; Jhatakia AD; Deng AX; Bee C; Deshpande S; Rangan VS; Bezman N; Gudmundsson O; Chen G J Am Soc Mass Spectrom; 2021 Jul; 32(7):1567-1574. PubMed ID: 33415981 [TBL] [Abstract][Full Text] [Related]
4. Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation. Debaene F; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S Anal Chem; 2013 Oct; 85(20):9785-92. PubMed ID: 24007193 [TBL] [Abstract][Full Text] [Related]
5. Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody. Schick AJ; Lundin V; Low J; Peng K; Vandlen R; Wecksler AT MAbs; 2022; 14(1):2028337. PubMed ID: 35072596 [TBL] [Abstract][Full Text] [Related]
6. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ MAbs; 2015; 7(3):470-82. PubMed ID: 25774965 [TBL] [Abstract][Full Text] [Related]
7. Characterization of Bispecific Antibody Production in Cell Cultures by Unique Mixed Mode Size Exclusion Chromatography. Jiang H; Xu W; Liu R; Gupta B; Kilgore B; Du Z; Yang X Anal Chem; 2020 Jul; 92(13):9312-9321. PubMed ID: 32497423 [TBL] [Abstract][Full Text] [Related]
8. A single homogeneous assay for simultaneous measurement of bispecific antibody target binding. Christian EA; Hussmann GP; Babu M; Prophet M; Mazor Y; Chen W; Grigoriadou C; Lin S J Immunol Methods; 2021 Sep; 496():113099. PubMed ID: 34224737 [TBL] [Abstract][Full Text] [Related]
9. Mapping of Fab-1:VEGF Interface Using Carboxyl Group Footprinting Mass Spectrometry. Wecksler AT; Kalo MS; Deperalta G J Am Soc Mass Spectrom; 2015 Dec; 26(12):2077-80. PubMed ID: 26419770 [TBL] [Abstract][Full Text] [Related]
10. Coupling Mixed-Mode Size Exclusion Chromatography with Native Mass Spectrometry for Sensitive Detection and Quantitation of Homodimer Impurities in Bispecific IgG. Yan Y; Xing T; Wang S; Daly TJ; Li N Anal Chem; 2019 Sep; 91(17):11417-11424. PubMed ID: 31373790 [TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody characterization by a combination of intact and site-specific/chain-specific LC/MS techniques. Duivelshof BL; Beck A; Guillarme D; D'Atri V Talanta; 2022 Jan; 236():122836. PubMed ID: 34635226 [TBL] [Abstract][Full Text] [Related]
12. Orthogonal Mass Spectrometry-Based Footprinting for Epitope Mapping and Structural Characterization: The IL-6 Receptor upon Binding of Protein Therapeutics. Li KS; Chen G; Mo J; Huang RY; Deyanova EG; Beno BR; O'Neil SR; Tymiak AA; Gross ML Anal Chem; 2017 Jul; 89(14):7742-7749. PubMed ID: 28621526 [TBL] [Abstract][Full Text] [Related]
13. Mapping the Binding Interface of VEGF and a Monoclonal Antibody Fab-1 Fragment with Fast Photochemical Oxidation of Proteins (FPOP) and Mass Spectrometry. Zhang Y; Wecksler AT; Molina P; Deperalta G; Gross ML J Am Soc Mass Spectrom; 2017 May; 28(5):850-858. PubMed ID: 28255747 [TBL] [Abstract][Full Text] [Related]
14. Mapping binding epitopes of monoclonal antibodies targeting major histocompatibility complex class I chain-related A (MICA) with hydrogen/deuterium exchange and electron-transfer dissociation mass spectrometry. Huang RY; Kuhne M; Deshpande S; Rangan V; Srinivasan M; Wang Y; Chen G Anal Bioanal Chem; 2020 Mar; 412(7):1693-1700. PubMed ID: 31993727 [TBL] [Abstract][Full Text] [Related]
15. Epitope characterization of anti-JAM-A antibodies using orthogonal mass spectrometry and surface plasmon resonance approaches. Terral G; Champion T; Debaene F; Colas O; Bourguet M; Wagner-Rousset E; Corvaia N; Beck A; Cianferani S MAbs; 2017; 9(8):1317-1326. PubMed ID: 28933642 [TBL] [Abstract][Full Text] [Related]
16. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Gu J; Ghayur T Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980 [TBL] [Abstract][Full Text] [Related]
17. Fast photochemical oxidation of proteins for epitope mapping. Jones LM; B Sperry J; A Carroll J; Gross ML Anal Chem; 2011 Oct; 83(20):7657-61. PubMed ID: 21894996 [TBL] [Abstract][Full Text] [Related]
18. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Li H; Er Saw P; Song E Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210 [TBL] [Abstract][Full Text] [Related]
19. Systematic workflow for studying domain contributions of bispecific antibodies to selectivity in multimodal chromatography. Parasnavis SS; Niu B; Aspelund M; Chung WK; Snyder M; Cramer SM Biotechnol Bioeng; 2022 Jan; 119(1):211-225. PubMed ID: 34687215 [TBL] [Abstract][Full Text] [Related]
20. Advances in mass spectrometry-based epitope mapping of protein therapeutics. Liu XR; Huang RY; Zhao F; Chen G; Tao L J Pharm Biomed Anal; 2022 Jun; 215():114754. PubMed ID: 35427962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]